tetano
Editor, Senior Moderator
Circ Rep
. 2024 Aug 29;6(9):366-371.
doi: 10.1253/circrep.CR-24-0084. eCollection 2024 Sep 10. Influenza Vaccination and Cardiovascular Events in Japanese Patients With Heart Failure - Findings From the PARALLEL-HF Trial
Hiroyuki Tsutsui[SUP] 1 [/SUP], Shin-Ichi Momomura[SUP] 2 [/SUP], Yoshihiko Saito[SUP] 3 [/SUP], Hiroshi Ito[SUP] 4 [/SUP], Kazuhiro Yamamoto[SUP] 5 [/SUP], Yasushi Sakata[SUP] 6 [/SUP], Tomomi Ohishi[SUP] 7 [/SUP], Chiyo Ito[SUP] 7 [/SUP]; PARALLEL-HF Investigators
Affiliations
Background: Influenza is associated with an increased risk for cardiovascular events in patients with heart failure (HF). This study aimed to investigate the prevalence of influenza vaccination among Japanese patients with HF enrolled in the PARALLEL-HF (Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) trial and the association between receiving influenza vaccination and cardiovascular events including death or HF hospitalization.
Methods and results: In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination. Influenza vaccination tended to be associated, though statistically not significant, with a lower risk for all-cause death (adjusted hazard ratio
: 0.67; 95% confidence interval [CI]: 0.32-1.39) and cardiopulmonary or influenza-related hospitalization or death (adjusted HR: 0.72; 95% CI: 0.46-1.11) in propensity score-adjusted models.
Conclusions: The influenza vaccination rate in Japanese patients with HFrEF who were well managed on guideline-directed medical therapy was suboptimal despite recommendations from clinical practice guidelines. However, importantly, it could be associated with better clinical benefits.
Keywords: Cardiovascular events; Heart failure; Influenza; Japanese; Vaccination.
. 2024 Aug 29;6(9):366-371.
doi: 10.1253/circrep.CR-24-0084. eCollection 2024 Sep 10. Influenza Vaccination and Cardiovascular Events in Japanese Patients With Heart Failure - Findings From the PARALLEL-HF Trial
Hiroyuki Tsutsui[SUP] 1 [/SUP], Shin-Ichi Momomura[SUP] 2 [/SUP], Yoshihiko Saito[SUP] 3 [/SUP], Hiroshi Ito[SUP] 4 [/SUP], Kazuhiro Yamamoto[SUP] 5 [/SUP], Yasushi Sakata[SUP] 6 [/SUP], Tomomi Ohishi[SUP] 7 [/SUP], Chiyo Ito[SUP] 7 [/SUP]; PARALLEL-HF Investigators
Affiliations
- PMID: 39262640
- PMCID: PMC11383541
- DOI: 10.1253/circrep.CR-24-0084
Background: Influenza is associated with an increased risk for cardiovascular events in patients with heart failure (HF). This study aimed to investigate the prevalence of influenza vaccination among Japanese patients with HF enrolled in the PARALLEL-HF (Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) trial and the association between receiving influenza vaccination and cardiovascular events including death or HF hospitalization.
Methods and results: In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination. Influenza vaccination tended to be associated, though statistically not significant, with a lower risk for all-cause death (adjusted hazard ratio
: 0.67; 95% confidence interval [CI]: 0.32-1.39) and cardiopulmonary or influenza-related hospitalization or death (adjusted HR: 0.72; 95% CI: 0.46-1.11) in propensity score-adjusted models.
Conclusions: The influenza vaccination rate in Japanese patients with HFrEF who were well managed on guideline-directed medical therapy was suboptimal despite recommendations from clinical practice guidelines. However, importantly, it could be associated with better clinical benefits.
Keywords: Cardiovascular events; Heart failure; Influenza; Japanese; Vaccination.